Hereditary Angioedema clinical trials at UCSD

• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

  Sorry, in progress, not accepting new patients

  The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at study start and then every 3 months until the study ends; data will also be collected by the study doctor during routine clinic visits.

  San Diego, California and other locations

Last updated: December 17, 2021